Saturday 17 October 2026 Export SGMOQ’s income statement to Excel — free account

Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024. In the quarter to March 2026, revenue fell 77.6%, EPS grew 42.9% and free cash flow grew 26.2%, each against the same quarter a year earlier.

0.11 0.03 −21.43%

Follow SGMOQ

Alert me

Market cap: $41.9M
P/E: 0.0×
Fwd P/E: −1.0×
Dividend yield: —
F-score: 3/9
Altman Z: −43.35
Beneish M: −5.11
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.11

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	2	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 41.89

Revenue 34.56

Net Income (123.33)

Free Cash Flow (90.46)

Net Debt (27.59)

Current Ratio 0.70

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.96)

P/S ratio 1.24

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 56.82%

Next Y EPS Growth 71.05%

Next Y revenue growth (74.97%)

Next 5Y EPS Growth 73.79%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 10.50%

10-year low 10-year high

EV/Sales against its own 10 years 9.13%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	81	42	21	28
Receivables	1	1	0	1
Inventory	—	—	—	—
Other	3	4	10	5
	94	52	36	37

	2023	2024	2025	Q'26
Payables	15	15	14	19
ST’ Debt	—	—	—	—
Other	—	—	—	—
	48	46	42	53

Compound Annual Growth %

	10y	5y	3y
Sales	0.00%	(19.66%)	(29.17%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	—	—	—	—
’25	6	18	1	14	40
’24	0	0	49	8	58
’23	158	7	9	2	176
’22	28	29	26	27	111
’21	26	28	29	28	111
’20	13	22	58	26	118

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	—	—	—	—
’25	(26)	(18)	(28)	(24)	(97)
’24	(49)	(27)	12	(3)	(67)
’23	(66)	(61)	(47)	(51)	(225)
’22	(59)	(54)	(54)	(57)	(224)
’21	(69)	(53)	(59)	(53)	(233)
’20	(19)	160	33	(4)	170

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	—	—	—	—
’25	(26)	(18)	(29)	(24)	(97)
’24	(49)	(27)	12	(4)	(67)
’23	(76)	(66)	(50)	(53)	(246)
’22	(62)	(59)	(58)	(65)	(244)
’21	(76)	(60)	(65)	(56)	(257)
’20	(23)	157	29	(8)	155

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.08)	—	—	—	—
’25	(0.14)	(0.08)	(0.11)	(0.11)	(0.44)
’24	(0.27)	(0.18)	0.04	(0.11)	(0.49)
’23	0.12	(0.66)	(0.59)	(0.34)	(1.48)
’22	(0.30)	(0.29)	(0.34)	(0.32)	(1.25)
’21	(0.32)	(0.33)	(0.33)	(0.26)	(1.23)
’20	(0.37)	(0.26)	(0.01)	(0.29)	(0.90)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.65	3.00	9.00	6.26	4.81	7.05	2.72	0.29	0.30	0.38	Analyst estimates 2026–2028 Powerpack
	High	9.22	18.40	27.50	13.91	19.43	17.53	7.99	3.76	3.18	1.51
People
People	Employees	131	182	302	354	413	431	478	405	183	142
	Revenue/emp, $m	0.15	0.20	0.28	0.29	0.29	0.26	0.23	0.44	0.32	0.28
Income, $m
Income, $m	Revenue	19	37	84	102	118	111	111	176	58	40
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(72)	(55)	(69)	(95)	(121)	(178)	(192)	(263)	(98)	(123)
	EBT margin, %	(369.65)	(149.23)	(81.57)	(93.16)	(102.19)	(160.79)	(172.37)	(149.18)	(169.74)	(312.25)
	Net income	(72)	(55)	(69)	(95)	(121)	(178)	(192)	(258)	(98)	(123)
	Depreciation	1	1	(3)	5	13	20	19	109	9	8
Per share, $
Per share, $	Revenue	0.27	0.47	0.87	0.91	0.88	0.77	0.72	1.01	0.29	0.14
	Earnings	(1.02)	(0.70)	(0.70)	(0.85)	(0.90)	(1.23)	(1.25)	(1.48)	(0.49)	(0.44)
	Cash flow	(0.93)	0.14	0.38	(1.29)	1.26	(1.61)	(1.45)	(1.29)	(0.33)	(0.35)
	Capex	(0.01)	(0.05)	(0.44)	(0.18)	(0.11)	(0.16)	(0.13)	(0.12)	0.00	0.00
	Free cash flow	(0.94)	0.10	(0.07)	(1.47)	1.15	(1.77)	(1.58)	(1.41)	(0.33)	(0.35)
	Book value	1.93	2.41	3.79	3.86	3.70	2.60	1.91	0.48	0.11	(0.05)
	Shares, m	71	78	97	112	134	145	154	174	202	280
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	11.28	37.48	13.18	9.16	17.76	9.79	4.35	0.55	3.56	2.98
	P/B	1.61	7.29	3.03	2.17	4.22	2.89	1.64	1.18	9.04	0.00
	EV/Sales	4.13	31.50	8.77	5.89	12.56	6.64	2.11	0.25	3.31	3.15
	EV/FCF	(1.20)	155.06	(113.65)	(3.66)	9.57	(2.87)	(0.96)	(0.18)	(2.63)	(1.27)
Cash, $m
Cash, $m	Operating cash flow	(66)	11	37	(144)	170	(233)	(224)	(225)	(67)	(97)
	Capex	(1)	(4)	(43)	(21)	(15)	(23)	(20)	(21)	0	0
	Free cash flow	(67)	7	(7)	(165)	155	(257)	(244)	(246)	(67)	(97)
Balance, $m
Balance, $m	Working capital	136	204	332	336	516	271	189	47	6	(7)
	Total debt	4	25	28	41	38	44	39	—	—	—
	Net debt	(139)	(219)	(372)	(362)	(641)	(377)	(278)	(81)	(42)	(21)
	Shareholders’ equity	136	188	367	433	497	375	295	83	23	(14)
Returns, %
Returns, %	ROA	(38.20)	(24.55)	(15.58)	(15.50)	(15.35)	(21.47)	(29.94)	(70.85)	(73.38)	(152.35)
	ROIC	0.00	0.00	0.00	(93.56)	0.00	0.00	(726.08)	(9,085.05)	0.00	0.00
	ROE	(43.61)	(33.67)	(24.62)	(23.80)	(26.02)	(40.86)	(57.37)	(136.47)	(185.39)	(2,891.84)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SER Serina Therapeutics, Inc.	$45.5M	— (loss-making)	— (loss-making)	+2,500.00% (above 0%: growing)	n/m	−76.82% (below 0%: shrinking)	100.00%	0.00%	Compare
ANVS Annovis Bio, Inc.	$44.8M	— (loss-making)	—	—	n/m	−329.18% (below 0%: shrinking)	—	0.00%	Compare
ALDX Aldeyra Therapeutics, Inc.	$44.5M	— (loss-making)	—	—	n/m	+46.09% (above 0%: growing)	0.00%	0.00%	Compare
CELU Celularity, Inc.	$43.2M	— (loss-making)	— (loss-making)	−66.34% (below 0%: shrinking)	n/m	+148.35% (above 0%: growing)	62.25%	(263.47%)	Compare
DWTX Dogwood Therapeutics, Inc	$42.5M	— (loss-making)	—	—	n/m	+10.31% (above 0%: growing)	—	0.00%	Compare
SGMOQ Sangamo Therapeutics, Inc.	$41.9M	— (loss-making)	— (loss-making)	−77.60% (below 0%: shrinking)	n/m	+26.21% (above 0%: growing)	100.00%	(2,215.40%)
VERU Veru Inc.	$41.6M	— (loss-making)	— (loss-making)	+287.06% (above 0%: growing)	n/m	+0.27% (above 0%: growing)	34.92%	0.00%	Compare
TIL Instil Bio, Inc.	$41.6M	— (loss-making)	—	—	n/m	+68.62% (above 0%: growing)	0.00%	0.00%	Compare
GRCE Grace Therapeutics, Inc.	$41.0M	— (loss-making)	— (loss-making)	+5,127.27% (above 0%: growing)	n/m	−78.85% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$42.8M	—	—	+1,393.53%	—	+5.29%	17.46%	0.00%

All 614 Biotechnology stocks →

Sangamo Therapeutics, Inc. (SGMOQ) key facts

Concern: Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024.
Concern: Sangamo Therapeutics, Inc. reported a net loss of $122.9 million, or a loss of $0.44 per share, for fiscal 2025.
Sangamo Therapeutics, Inc. (SGMOQ) is a Biotechnology company in the Healthcare sector.
As of October 16, 2026, SGMOQ traded at $0.11, a market capitalization of $41.9 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.2× sales.
Return on equity was −2,891.8% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −43.35 (distress zone) for fiscal 2025.